Dengvaxia doses — EDWIN BACASMAS
Drug manufacturer Sanofi Pasteur on Monday stood firm on its position that it will not refund the Philippine government’s P3-billion used purchase of anti-dengue vaccine Dengvaxia.
Responding to the second request made by the Department of Health (DOH), Sanofi also turned down its demand for financial support and indemnification fund.
“We respectfully declined both requests. We stand firmly behind our product. Refunding the used doses of Dengvaxia would imply that the vaccine is ineffective, which is not the case. And at this time, there is also no known circumstance requiring indemnification,” Sanofi said Monday in a statement.
“Dengvaxia, like all other vaccines, has never claimed 100% efficacy in its approved label,” Sanofi said “Dengvaxia vaccination in the Philippines will provide a net reduction in dengue disease, including severe dengue.”
READ: Sanofi rejects PH’s demand for full refund of P3B-worth of Dengvaxia
Sanofi said they are willing to sit down with the Department of Health to find other ways to assist in fighting dengue and restoring public trust in vaccines.
“Our concern and empathy remains with any and all individuals and families that have been affected by these difficult circumstances,” Sanofi added. /je